A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Phase I First-in-Human, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Tingbo Liang
- 電話番号:+86 13666676121
- メール:liangtingbo_trial@163.com
研究連絡先のバックアップ
- 名前:Xueli Bai
- メール:baixueli_trial@163.com
研究場所
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 募集
- Fujian Cancer Hospital
-
コンタクト:
- Zengqing Guo
-
-
Henan
-
Zhengzhou、Henan、中国、450000
- まだ募集していません
- The First Affiliated Hospital of Zhengzhou University
-
コンタクト:
- Shuiling Jin
-
-
Hunan
-
Changsha、Hunan、中国、410013
- まだ募集していません
- Hunan Cancer Hospital
-
コンタクト:
- Haiyan Yang
-
コンタクト:
- Xingxiang Pu
-
-
Liaoning
-
Shenyang、Liaoning、中国、110000
- まだ募集していません
- The First Hospital of China Medical University
-
コンタクト:
- Yunpeng Liu
-
-
Shandong
-
Jinan、Shandong、中国、250117
- まだ募集していません
- Cancer Hospital of Shandong First Medical University
-
コンタクト:
- Shuqin Ni
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- 募集
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
コンタクト:
- Tingbo Liang
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- In dose-escalation cohorts (Part 1), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- In the dose-expansion cohorts (Part 2), histologically or cytologically confirmed selected advanced solid tumors.
- Subjects must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
- Life expectancy ≥12 weeks.
- Patients of childbearing potential (male and female) must agree to use reliable methods of contraception until at least 180 days after the last dose.
Exclusion Criteria:
- Symptomatic brain metastases.
- Serious non-healing wounds, ulcers or fractures.
- Toxicity from previous treatment has to restore to ≤ grade 1.
- Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to enrollment.
- Use of aspirin (> 325 mg/day) within 6 months prior to the first dose.
- Active hepatitis B or hepatitis C.
- Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- Known hereditary or acquired predisposition to bleeding and thrombosis.
- History of gastrointestinal perforation, gastrointestinal bleeding, fistula, or any life-threatening bleeding event within 6 months prior to enrollment.
- Prior permanent discontinuation of PD-(L)1 and/or VEGF monoclonal antibody because of immune/anti-angiogenesis toxicities, or history of Grade ≥3 immune/anti-angiogenesis-related AEs
- Known or suspected active autoimmune disease.
- Patients with proteinuria at screening (Urine protein >2+ at screening, or 2+ urine protein accompanied by 24-h urine protein ≥1 g/24 h).
- History of myocardial infarction or stroke within 6 months prior to enrollment.
- Subjects with clinically significant cardiovascular disease within 6 months prior to the first dose.
- Pregnant and lactating women.
- Known allergies to any excipient in the study drug.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:SIM0689 for Injection
One intravenous infusion of SIM0689 for Injection, 28 days or 21 days as a treatment cycle.
|
SIM0689 for Injection is a Programmed Cell Death Protein 1(PD1) / Vascular Endothelial Growth Factor (VEGF) bispecific antibody.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose-limiting toxicity (DLT) (Dose escalation)
時間枠:at the end of Cycle 1 (each cycle is 28 days)
|
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria.
|
at the end of Cycle 1 (each cycle is 28 days)
|
|
Maximum tolerated dose (MTD)and / or Recommended dose (RD) (Dose escalation)
時間枠:Up to approximately 2 years
|
The MTD is defined as the dose of SIM0689 with an estimated toxicity rate closest to the target toxicity rate of 27%; RD stands for Recommended Dose, which will be selected based on the evaluation of all available pharmacokinetics, pharmacodynamic, efficacy, safety, and tolerability data |
Up to approximately 2 years
|
|
Objective Response Rate (ORR) (Dose expansion)
時間枠:Up to approximately 2 years
|
ORR is the proportion of participants with complete response(CR)or partial response (PR) assessed according to RECIST v1.1.
|
Up to approximately 2 years
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse event rate
時間枠:up to approximately 2 years
|
The occurrence of all adverse events (AEs), evaluated by Common Terminology Criteria for Adverse Events (CTCAE) 6.0.
|
up to approximately 2 years
|
|
Pharmacokinetics: The area under the curve (AUC)
時間枠:up to approximately 2 years
|
The area under the curve (AUC) of serum concentration of SIM0689
|
up to approximately 2 years
|
|
Pharmacokinetics: Peak concentration (Cmax)
時間枠:Up to approximately 2 years
|
Maximum observed concentration (Cmax) of SIM0689
|
Up to approximately 2 years
|
|
Pharmacokinetics: T1/2
時間枠:Up to approximately 2 years
|
Terminal half-life (T1/2)
|
Up to approximately 2 years
|
|
Pharmacokinetics: Tmax
時間枠:Up to approximately 2 years
|
Time to maximum concentration
|
Up to approximately 2 years
|
|
Immunogenicity
時間枠:Up to approximately 2 years
|
Titer of serum anti-SIM0689 antibodies
|
Up to approximately 2 years
|
|
Immunogenicity
時間枠:Up to approximately 2 years
|
Incidence rate of serum anti-SIM0689 antibodies
|
Up to approximately 2 years
|
|
Immunogenicity
時間枠:Up to approximately 2 years
|
Duration of serum anti-SIM0689 antibodies
|
Up to approximately 2 years
|
協力者と研究者
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。